Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript

So we feel good about that. We like, by the way, on Haystack it’s a tumor-informed test. Again, we feel good about the technology. As we mentioned earlier, we’ve signed up 20 pre-launch customers for this early experience program. These are a broad base set of customers from community-based oncologists to academic medical centers. So, we like the mix of customers that have come to us right away for this. Once we wrap this early experience program up, we’ll be launching on a national basis later this year.

Sam Samad : Andrew, just to add, this is Sam from a dilution standpoint. So our expectations this year have not changed. It’s still in total 35% dilution, which is $0.20 of incremental dilution versus last year. For next year, we expect less dilution from Haystack. So on a year-over-year basis, it’s actually a tailwind, and then we expect to be basically to start being neutral to a creative as we look towards ‘26. So, nothing has changed from a dilution or financial expectations, and we’re really thrilled about the interest in the early experience program that Jim referenced.

Operator: And that was the final question.

Jim Davis : All right, thanks, operator. And thanks again for joining our call today. We really appreciate your continued support. Have a good day, everyone.

Operator: Thank you for participating in the Quest Diagnostics first quarter 2024 conference call. A transcript of prepared remarks on this call will be posted later today on Quest Diagnostics’ website at www.QuestDiagnostics.com. A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 203-369-0197 for international callers or 866-363-1809 for domestic callers. Telephone replays will be available from approximately 10.30 Eastern Time on April 23, 2024 until midnight Eastern Time May 7, 2024. Goodbye.